Influenza virus vaccine (Fluad) - Seqirus

Drug Profile

Influenza virus vaccine (Fluad) - Seqirus

Alternative Names: Chiromas; Fluad; Fluad Pediatric; Gripguard; Influpozzi Adiuvato; MF59-adjuvanted seasonal influenza vaccine (Fluad) - Seqirus; Trivalent Influenza Vaccine (Fluad)- Seqirus

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Vaccines
  • Developer Novartis Vaccines; Seqirus
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
  • 23 Aug 2017 Launched for Influenza virus infections (In the elderly, Prevention) in United Kingdom (IM)
  • 22 Aug 2017 Registered for Influenza virus infections (In the elderly, Prevention) in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top